Supernus Pharmaceuticals

SUPNApproved

Rockville, United StatesFounded 2005supernus.com

Supernus Pharmaceuticals is a commercial-stage biopharma leader in CNS disorders, leveraging deep expertise in drug delivery and product development to build a diversified portfolio. The company has demonstrated consistent growth, earning recognition on lists like Forbes' America's Best Small Companies and Fortune's 100 Fastest Growing Companies. With a foundation of marketed products generating revenue, Supernus is strategically advancing mid- and late-stage pipeline candidates while maintaining a patient-centric culture and operational excellence.

Market Cap

$2.8B

Founded

2005

Focus

Small Molecules

SUPN · Stock Price

USD 47.76+15.73 (+49.11%)

Historical price data

AI Company Overview

Technology Platform

Proprietary drug delivery technologies focused on developing novel, improved formulations and extended-release products for central nervous system (CNS) conditions.

Pipeline Snapshot

75 drugs in pipeline, 25 in Phase 3

Drug	Indication	Stage
APOKYN + L-dopa + Trimethobenzamide	Parkinson's Disease	Approved
SPN-812	Attention-Deficit/Hyperactivity Disorder (ADHD)	Approved
SPN-538 + Placebo	Migraine Disorders	Approved
APOKYN	Parkinson's Disease	Approved
SPN-812 (600mg, QD)	Healthy Lactating Women	Approved

Funding History

Total raised: $60M

IPO$60MUndisclosedFeb 8, 2012

FDA Approved Drugs

ONAPGONDAFeb 3, 2025

QELBREENDAApr 2, 2021

GOCOVRINDAAug 24, 2017

Opportunities

Significant opportunities exist in expanding the label and market share for Qelbree in ADHD, advancing SPN-820/821 in the high-need treatment-resistant depression space, and leveraging the recent acquisition of Sage Therapeutics to broaden the CNS portfolio.

The company's proven drug delivery platform can be applied to develop additional differentiated CNS assets.

Risk Factors

Key risks include clinical trial failures for mid-stage pipeline candidates (SPN-820/821, SPN-817), intense competition and potential generic erosion in core ADHD and epilepsy markets, regulatory challenges for new CNS drugs, and execution risks associated with integrating the Sage Therapeutics acquisition.

Competitive Landscape

Supernus competes with large pharma CNS divisions and specialized biotechs in ADHD, epilepsy, and depression. Its main differentiation is its focused expertise in CNS drug delivery, leading to commercially successful extended-release products, a diversified revenue base from multiple marketed drugs, and a targeted commercial approach within neurology/psychiatry.

Publications

Patents

Pipeline

FDA Approvals